AI assistant
NEOGENOMICS INC — Director's Dealing 2015
Apr 24, 2015
32227_dirs_2015-04-24_f99c5e72-566e-4c66-8252-3095349b95e1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2015-04-16
Reporting Person: BRODIE STEVEN G. (Chief Scientific Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4482 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.48 | 2016-05-16 | Common Stock (50000) | Direct | |
| Stock Option (Right to Buy) | $1.69 | 2017-04-12 | Common Stock (10000) | Direct | |
| Stock Option (Right to Buy) | $3.76 | 2018-04-16 | Common Stock (10000) | Direct | |
| Stock Option (Right to Buy) | $3.45 | 2019-03-05 | Common Stock (20000) | Direct |
Footnotes
F1: On May 16, 2011 Dr. Brodie was granted 50,000 stock options. The options vest ratably over the first four anniversaries of the grant date.
F2: On April 12, 2012 Dr. Brodie was granted 10,000 stock options. There was immediate vesting of 2,500 shares and then 2,500 shares will vest on the next three anniversary dates of the grant date.
F3: On April 16, 2013 Dr. Brodie was granted 10,000 stock options. These options will vest ratably over the next three anniversary dates of the grant date.
F4: On March 5, 2014 Dr. Brodie was granted 20,000 stock options. The options will vest ratably over the next three anniversary dates of the grant date.